ALS ONE RADICAVA STATEMENT & RESOURCES

Posted on May 10th, 2017

ALS ONE commends the Food and Drug Administration’s (FDA) announcement today that it has expedited approval of Radicava (edaravone), a new treatment for ALS.  This is a huge victory for the ALS community as it is the first drug to be approved by the FDA since Riluzole was approved 22 years ago.  We hope that this is the first of many treatment options to come as there are many promising clinical trials currently underway.

The ALS ONE science & care teams want to ensure all patients are aware that bringing newly approved treatments to market can take some time and we anticipate that Radicava will likely be available in the US in the next 90 days. We will keep you informed with any new updates.

For questions about Radicava, please feel free to contact the following services set up by the company:

The approval of Radicava is big success for ALS research and most importantly a great victory for all ALS patients.